Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04155424
Recruitment Status : Not yet recruiting
First Posted : November 7, 2019
Last Update Posted : November 7, 2019
Sponsor:
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).

Condition or disease Intervention/treatment Phase
Neuromyelitis Optica Neuromyelitis Optica Spectrum Disorder Drug: Eculizumab Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder
Estimated Study Start Date : November 2019
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : December 2024


Arm Intervention/treatment
Experimental: Eculizumab

All participants will receive open-label eculizumab by intravenous infusion during the Primary Treatment Period, starting on Day 1 and for a total of 52/53 weeks. The dosing regimen will be based on the participant's body weight. As body weight changes during the study, the participant's weight cohort and dose may change accordingly.

After completing the 52/53-week Primary Treatment Period, participants may continue receiving eculizumab in the Extension Treatment Period for 104 weeks.

Drug: Eculizumab
Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
Other Name: Soliris




Primary Outcome Measures :
  1. Change From Baseline In The Annualized Relapse Rate At 52/53 Weeks [ Time Frame: Baseline, Week 52/53 ]
  2. Time To First Relapse [ Time Frame: Baseline up to Week 52/53 ]

Secondary Outcome Measures :
  1. Change From Baseline In Expanded Disability Status Scale (EDSS) Score At 52/53 Weeks In Participants ≥5 Years Of Age [ Time Frame: Baseline, Week 52/53 ]
  2. Change From Baseline In The Hauser Ambulatory Index Score At 52/53 Weeks [ Time Frame: Baseline, Week 52/53 ]
  3. Change From Baseline In Pediatric Quality Of Life Inventory (PedsQL) At 52/53 Weeks In Participants ≥5 Years Of Age [ Time Frame: Baseline, Week 52/53 ]
  4. Change From Baseline In Pediatric Quality Of Life Inventory Parent Proxy (PedsQL Parent Proxy) At 52/53 Weeks In Participants < 5 Years Of Age [ Time Frame: Baseline, Week 52/53 ]
  5. Change From Baseline In Visual Acuity As Measured By The Snellen Or LEA Symbols Eye Chart Examination At 52/53 Weeks [ Time Frame: Baseline, Week 52/53 ]
  6. Change From Baseline In Confrontational Visual Fields As Measured During Ophthalmologic Examination At 52/53 Weeks [ Time Frame: Baseline, Week 52/53 ]
  7. Change From Baseline In Color Vision As Measured During Ophthalmologic Examination At 52/53 Weeks [ Time Frame: Baseline, Week 52/53 ]
  8. Serum Eculizumab Concentration Over Time [ Time Frame: Baseline through Week 52/53 ]
  9. Serum Free Complement Protein 5 Concentrations Over Time [ Time Frame: Baseline through Week 52/53 ]
  10. In Vitro Hemolytic Activity Over Time [ Time Frame: Baseline through Week 52/53 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female participants aged 2 years to < 18 years with body weight ≥ 10 kilograms (kg).
  2. Vaccinated against Neisseria meningitidis within 3 years prior to, or at the time of initiating eculizumab. Participants who initiate study drug treatment less than 2 weeks after receiving a meningococcal vaccine must receive appropriate prophylactic antibiotics until 2 weeks after the vaccination.
  3. Documented vaccination against haemophilus influenzae type b and streptococcus pneumoniae infections at least 2 weeks prior to dosing as per local and country-specific immunization guidelines for the appropriate age group.
  4. Anti-aquaporin-4 antibody-positive and diagnosis of NMOSD as defined by the 2015 International Panel for Neuromyelitis Optica Diagnosis criteria.
  5. Historical Relapse Rate of at least 2 relapses in the last 2 years, and with at least 1 relapse in the year prior to Screening.
  6. EDSS score ≤ 7.
  7. Participants who enter the study receiving supportive immunosuppressive therapies (ISTs) for the prevention of relapse, either in combination or monotherapy, must be on a stable dosing regimen of adequate duration.
  8. Female participants of childbearing potential must have a negative pregnancy test (serum human chorionic gonadotropin) at Screening and follow protocol-specified contraception guidance for avoiding pregnancy while on treatment and for 5 months after the last dose of eculizumab.
  9. Male participants with a female spouse/partner of childbearing potential or a pregnant or breastfeeding spouse or partner must agree to use double barrier contraception (male condom plus appropriate barrier method for the female partner) while on treatment and for at least 5 months after the last dose of eculizumab.

Exclusion Criteria:

  1. Parent or legal guardian is an Alexion employee.
  2. Pregnant, breastfeeding, or intending to conceive during the course of the study.
  3. Participants known to be human immunodeficiency virus positive or with congenital immunodeficiency.
  4. Unresolved meningococcal or other serious infection.
  5. Any unresolved acute or chronic systemic bacterial or other infection that is clinically significant in the opinion of the Investigator and has not been treated with appropriate antibiotics.
  6. Use of rituximab or other biologicals such as tocilizumab within 6 months prior to Screening.
  7. Use of mitoxantrone within 3 months prior to Screening.
  8. Use of intravenous immunoglobulin or plasma exchange within 3 weeks prior to Screening.
  9. Use of immunomodulatory therapies for multiple sclerosis within 3 months prior to Screening.
  10. Has previously received treatment with eculizumab or other complement inhibitors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04155424


Contacts
Layout table for location contacts
Contact: Alexion Pharmaceuticals, Inc. 855-752-2356 clinicaltrials@alexion.com

  Show 23 Study Locations
Sponsors and Collaborators
Alexion Pharmaceuticals

Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04155424     History of Changes
Other Study ID Numbers: ECU-NMO-303
2019-001829-26 ( EudraCT Number )
First Posted: November 7, 2019    Key Record Dates
Last Update Posted: November 7, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alexion Pharmaceuticals:
Neuromyelitis Optica
Neuromyelitis Optica Spectrum Disorder
Devic's Disease
Transverse Myelitis
Optic Neuritis
Relapse
Eculizumab
Soliris
CNS Autoimmune Disorders
Demyelinating Disorders
NMO
NMOSD
Additional relevant MeSH terms:
Layout table for MeSH terms
Eye Diseases
Neuromyelitis Optica
Disease
Pathologic Processes
Myelitis, Transverse
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Optic Neuritis
Optic Nerve Diseases
Cranial Nerve Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases